BioInvent has presented Phase I clinical data for BI-1910 at the Society for Immunotherapy of Cancer (SITC) 2025 scientific conference. The results show that the treatment provided stable disease in 12 out of 26 patients with advanced solid tumors, five of whom showed disease control for more than six months. Despite the promising results, the company has chosen to pause the development of BI-1910 in order to focus resources on its lead programs BI-1808 and BI-1206.
Read the full article at biostock.se:
BioInvent presents positive Phase I data for BI-1910
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/